Patient individual phase gating for stereotactic radiation therapy of early stage non-small cell lung cancer (NSCLC).
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung
/ diagnostic imaging
Dose-Response Relationship, Radiation
Four-Dimensional Computed Tomography
Humans
Lung Neoplasms
/ diagnostic imaging
Middle Aged
Motion
Radiosurgery
Radiotherapy Dosage
Radiotherapy Planning, Computer-Assisted
Respiration
Tumor Burden
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 03 2021
12 03 2021
Historique:
received:
28
05
2020
accepted:
23
02
2021
entrez:
13
3
2021
pubmed:
14
3
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Stereotactic body radiotherapy (SBRT) applies high doses and requires advanced techniques to spare surrounding tissue in the presence of organ motion. In this work patient individual phase gating is investigated. We studied peripheral and central primary lung tumors. The internal target volume (ITV) was defined including different numbers of phases picked from a 4D Computed tomography (CT) defining the gating window (gw). Planning target volume (PTV) reductions depending on the gw were analyzed. A treatment plan was calculated on a reference phase CT (rCT) and the dose for each breathing phase was calculated and accumulated on the rCT. We compared the dosimetric results with the dose calculated when all breathing phases were included for ITV definition. GWs including 1 to 10 breathing phases were analyzed. We found PTV reductions up to 38.4%. The mean reduction of the lung volume receiving 20 Gy due to gating was found to be 25.7% for peripheral tumors and 16.7% for central tumors. Gating considerably reduced esophageal doses. However, we found that simple reduction of the gw does not necessarily influence the dose in a clinically relevant range. Thus, we suggest a patient individual definition of the breathing phases included within the gw.
Identifiants
pubmed: 33712667
doi: 10.1038/s41598-021-85031-w
pii: 10.1038/s41598-021-85031-w
pmc: PMC7955128
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5870Références
Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1120-8
pubmed: 24661665
Support Care Cancer. 2013 Jan;21(1):211-8
pubmed: 22661073
Ann Lung Cancer. 2019;3(1):75-83
pubmed: 31942567
Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):326-32
pubmed: 20117285
Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):253-60
pubmed: 16111596
Rep Pract Oncol Radiother. 2019 Jan-Feb;24(1):97-104
pubmed: 30532657
Radiother Oncol. 2010 Jul;96(1):48-54
pubmed: 20430460
J Natl Compr Canc Netw. 2017 Apr;15(4):504-535
pubmed: 28404761
Radiat Oncol. 2009 Jan 12;4:1
pubmed: 19138400
Radiat Oncol. 2018 Apr 2;13(1):57
pubmed: 29606150
Radiat Oncol. 2016 Sep 22;11(1):125
pubmed: 27659780
J Appl Clin Med Phys. 2010 Jun 29;11(3):3223
pubmed: 20717090
Pract Radiat Oncol. 2017 Sep - Oct;7(5):295-301
pubmed: 28596092
Radiother Oncol. 2009 Dec;93(3):430-5
pubmed: 19822373
Phys Med Biol. 2003 Jan 7;48(1):45-62
pubmed: 12564500
Lung Cancer (Auckl). 2018 Nov 05;9:103-110
pubmed: 30464667
Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21
pubmed: 28881918
J Clin Oncol. 2006 Oct 20;24(30):4833-9
pubmed: 17050868
Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):618-25
pubmed: 19147026
J Thorac Oncol. 2008 Dec;3(12):1433-8
pubmed: 19057269
JAMA. 2010 Mar 17;303(11):1070-6
pubmed: 20233825
Radiother Oncol. 2010 May;95(2):172-7
pubmed: 20227779
Strahlenther Onkol. 2014 Jan;190(1):26-33
pubmed: 24052011
J Thorac Oncol. 2013 Aug;8(8):1050-8
pubmed: 23817193
J Thorac Dis. 2014 Apr;6(4):303-18
pubmed: 24688775
Clin Oncol (R Coll Radiol). 2014 Feb;26(2):67-80
pubmed: 24290238
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):967-73
pubmed: 21377293